Evidence map›Paper›PMID 41547846›Full record

ArticleNPJ breast cancer2026

Host-derived interleukin-1α drives tumor immunosuppression by reprogramming tumor-associated myeloid cells.

Manikanda Raja Keerthi Raja, Gourab Gupta, Grace Atkinson, Katie Kathrein, Alissa Armstrong, R Michael Gower, Igor B Roninson, Eugenia V Broude, Mengqian Chen, Hao Ji and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Manikanda Raja Keerthi Raja *Department of Biological Sciences, University of South Carolina, Columbia, SC, USA.
Gourab Gupta *Department of Biological Sciences, University of South Carolina, Columbia, SC, USA.
Grace AtkinsonDepartment of Biological Sciences, University of South Carolina, Columbia, SC, USA.
Katie KathreinDepartment of Biological Sciences, University of South Carolina, Columbia, SC, USA.
Alissa ArmstrongDepartment of Biological Sciences, University of South Carolina, Columbia, SC, USA.
R Michael GowerDepartment of Chemical Engineering and Biomedical Engineering, University of South Carolina, Columbia, SC, USA.
Igor B RoninsonDepartment of Drug Discovery & Biomedical Sciences (DDBS), College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Eugenia V BroudeDepartment of Drug Discovery & Biomedical Sciences (DDBS), College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Mengqian ChenDepartment of Drug Discovery & Biomedical Sciences (DDBS), College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Hao JiDepartment of Drug Discovery & Biomedical Sciences (DDBS), College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Chang-Uk LimDepartment of Drug Discovery & Biomedical Sciences (DDBS), College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Hongjun WangDepartment of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ, USA.
Daping FanDepartment of Cell Biology and Anatomy, University of South Carolina School of Medicine, Columbia, SC, USA.
Peisheng XuDepartment of Drug Discovery & Biomedical Sciences (DDBS), College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Jie LiDepartment of Chemistry and Biochemistry, University of South Carolina, Columbia, SC, USA.
Gang ZhouGeorgia Cancer Center, Department of Medicine, Medical College of Georgia, Augusta, GA, USA.
Hexin ChenDepartment of Biological Sciences, University of South Carolina, Columbia, SC, USA. hchen@biol.sc.edu.

Funding

Preventing adaptive drug resistance through Mediator kinase inhibitionR01CA266027 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Hexin Chen, Mengqian Chen · 2022 to 2026
$3.0M
Cancer cell selective killing nanoparticle for advanced ovarian cancer treatmentR01CA263747 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI Peisheng Xu · 2022 to 2026
$1.7M
Nanoparticle delivered miR-489 rejuvenates anthracycline-based chemotherapyR21CA252360 · NCI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI CHEN, HEXIN, XU, PEISHENG · 2020 to 2021
$397k
National Cancer Institute, United States R01CA266027; R21 CA252360NCI NIH HHS R01 CA263747NCI NIH HHS R01 CA266027NCI NIH HHS R21 CA252360
6 · The paper itself

Abstract

Myeloid cells are highly heterogeneous and play key roles in establishing an immunosuppressive tumor microenvironment (TME), but the mechanisms controlling their differentiation remain unclear. Using orthotopic murine breast cancer models, we investigated how interleukin-1α (IL-1α) influences this process. Deletion of host Il1α resulted in rejection of transplanted tumors. Single-cell RNA sequencing identified CX3CR1⁺ macrophages as the main source of IL-1α in the TME. Il1α deficiency disrupted monocyte-macrophage differentiation, reducing CX3CR1⁺ macrophages and increasing iNOS⁺ macrophages. Myeloid cells from Il1α

Identifiers

PMID41547846
PMCPMC12910057

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.